Brokerages Set Insulet Co. (NASDAQ:PODD) Price Target at $277.13

Shares of Insulet Co. (NASDAQ:PODD) have been assigned an average recommendation of “Moderate Buy” from the fifteen analysts that are presently covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The average 1 year price target among analysts that have covered the stock in the last year is $277.13.

Several analysts have recently weighed in on PODD shares. Morgan Stanley lifted their price target on shares of Insulet from $234.00 to $317.00 and gave the company an “overweight” rating in a research note on Monday, November 11th. Sanford C. Bernstein began coverage on Insulet in a research report on Wednesday, November 6th. They set an “outperform” rating and a $300.00 target price for the company. Citigroup increased their price target on Insulet from $283.00 to $310.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. JPMorgan Chase & Co. lifted their price objective on Insulet from $280.00 to $330.00 and gave the company an “overweight” rating in a report on Thursday, December 12th. Finally, Canaccord Genuity Group upped their price objective on shares of Insulet from $269.00 to $304.00 and gave the stock a “buy” rating in a research note on Monday, December 9th.

Insiders Place Their Bets

In other news, EVP Eric Benjamin sold 12,394 shares of the business’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the sale, the executive vice president now owns 11,383 shares in the company, valued at approximately $3,187,240. The trade was a 52.13 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Lauren Budden sold 915 shares of the stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total transaction of $252,192.30. Following the completion of the transaction, the chief accounting officer now directly owns 5,733 shares of the company’s stock, valued at $1,580,129.46. The trade was a 13.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.47% of the company’s stock.

Hedge Funds Weigh In On Insulet

Hedge funds have recently made changes to their positions in the company. CANADA LIFE ASSURANCE Co increased its holdings in shares of Insulet by 18.5% in the fourth quarter. CANADA LIFE ASSURANCE Co now owns 35,955 shares of the medical instruments supplier’s stock valued at $9,378,000 after purchasing an additional 5,626 shares during the period. Marshall Wace LLP boosted its position in Insulet by 29.6% in the fourth quarter. Marshall Wace LLP now owns 486,516 shares of the medical instruments supplier’s stock valued at $127,015,000 after buying an additional 111,119 shares during the last quarter. Jump Financial LLC acquired a new position in Insulet in the 4th quarter worth approximately $393,000. Guggenheim Capital LLC raised its position in Insulet by 25.6% during the 4th quarter. Guggenheim Capital LLC now owns 22,355 shares of the medical instruments supplier’s stock worth $5,836,000 after buying an additional 4,555 shares during the last quarter. Finally, Canada Post Corp Registered Pension Plan acquired a new stake in Insulet during the 4th quarter valued at approximately $324,000.

Insulet Trading Up 0.9 %

Shares of PODD opened at $282.12 on Friday. The firm has a market capitalization of $19.79 billion, a price-to-earnings ratio of 48.31, a PEG ratio of 3.61 and a beta of 1.23. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. Insulet has a 1-year low of $160.19 and a 1-year high of $289.46. The company has a 50-day moving average of $271.44 and a 200 day moving average of $243.41.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.